AirSculpt Technologies (NASDAQ:AIRS) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

AirSculpt Technologies (NASDAQ:AIRS) announced its quarterly earnings data on Friday. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01), Zacks reports. AirSculpt Technologies had a negative net margin of 7.39% and a negative return on equity of 4.98%. The business had revenue of $39.39 million during the quarter, compared to analyst estimates of $39.20 million.

Here are the key takeaways from AirSculpt Technologies’ conference call:

• AirSculpt reported $39.4 million in Q1 revenue (flat YoY) and achieved its first positive same-center sales in over two years, with same-store revenue up ~1% excluding London and a 19% sequential improvement.
• Gross margin expanded to about 60% (cost of services $15.6M), but adjusted EBITDA fell to $3.3 million (8.4% of revenue) as SG&A rose roughly $0.8M due to deliberate marketing investments.
• The balance sheet strengthened—cash of $16.7 million, $11 million of debt repaid in the quarter, gross debt of ~$46 million, leverage below 2.5x, and management is working on a term‑loan refinance while remaining in covenant compliance.
• Management highlighted a large long‑term opportunity from GLP-1 drug adoption (projected growth to 25M users by 2030) and is piloting skin‑tightening and skin‑removal procedures (150 skin excisions in Q1) that could unlock an estimated >$100M across centers, though these services are not yet a meaningful revenue driver.
• The company reaffirmed FY26 guidance of $151M–$157M in revenue and $15M–$17M in adjusted EBITDA, expects sequential improvement in Q2, and does not plan any de novo center openings in 2026 while prioritizing same‑center growth.

AirSculpt Technologies Price Performance

Shares of NASDAQ:AIRS opened at $4.66 on Thursday. The company’s fifty day moving average price is $2.77 and its 200-day moving average price is $3.34. The company has a debt-to-equity ratio of 0.39, a current ratio of 0.75 and a quick ratio of 0.55. The firm has a market capitalization of $328.76 million, a price-to-earnings ratio of -27.41 and a beta of 1.99. AirSculpt Technologies has a one year low of $1.51 and a one year high of $12.00.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded AirSculpt Technologies from a “sell” rating to a “hold” rating in a research note on Sunday, April 5th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $6.00.

Insiders Place Their Bets

In other AirSculpt Technologies news, major shareholder Jorey Chernett purchased 40,000 shares of AirSculpt Technologies stock in a transaction on Friday, April 17th. The shares were acquired at an average cost of $2.54 per share, for a total transaction of $101,600.00. Following the completion of the transaction, the insider directly owned 7,053,761 shares of the company’s stock, valued at approximately $17,916,552.94. The trade was a 0.57% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders purchased 810,150 shares of company stock valued at $1,987,624. Insiders own 44.60% of the company’s stock.

Institutional Investors Weigh In On AirSculpt Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Invesco Ltd. bought a new stake in AirSculpt Technologies in the 1st quarter worth $56,000. Creative Planning grew its position in shares of AirSculpt Technologies by 32.2% in the 2nd quarter. Creative Planning now owns 13,225 shares of the company’s stock worth $64,000 after buying an additional 3,224 shares during the last quarter. WINTON GROUP Ltd purchased a new position in shares of AirSculpt Technologies during the second quarter valued at approximately $106,000. Jane Street Group LLC bought a new position in shares of AirSculpt Technologies during the second quarter valued at approximately $60,000. Finally, Balyasny Asset Management L.P. increased its position in shares of AirSculpt Technologies by 128.5% during the second quarter. Balyasny Asset Management L.P. now owns 1,113,843 shares of the company’s stock valued at $5,380,000 after buying an additional 626,309 shares during the period. Institutional investors own 91.54% of the company’s stock.

AirSculpt Technologies Company Profile

AirSculpt Technologies, Inc (NASDAQ: AIRS) is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction.

Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes.